KITE PHARMA (KITE)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

2225 COLORADO AVENUE SANTA MONICA, CA 90404

Kite Pharma, Inc. develops and manufacturers pharmaceuticals. The company offers and designs cancer immunotherapeutic products and therapy designed to restoring the patient's immune system to recognize and eradicate tumors.

View SEC Filings from KITE instead.

View recent insider trading info

Funds Holding KITE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KITE BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BONDERMAN DAVID

  • Director
No longer subject to file 2017-10-03 0

CHAMPSI FARAH

  • Director
No longer subject to file 2017-10-03 0

BUTITTA CYNTHIA M CHIEF OPERATING OFFICER

  • Officer
No longer subject to file 2017-10-03 0

DOUMANI ROY

  • Director
No longer subject to file 2017-10-03 0

CLARK IAN T

  • Director
No longer subject to file 2017-10-03 0

KIM HELEN SUSAN EVP, BUSINESS DEVELOPMENT

  • Officer
No longer subject to file 2017-10-03 0

PEACOCK JONATHAN M

  • Director
No longer subject to file 2017-10-03 0

HUMER FRANZ B

  • Director
No longer subject to file 2017-10-03 0

RUCHEFSKY STEVEN B

  • Director
No longer subject to file 2017-10-03 0

NUSSBAUM RAN

  • Director
No longer subject to file 2017-10-03 0

WIEZOREK JEFFREY SVP CLINICAL DEVELOPMENT

  • Officer
No longer subject to file 2017-10-03 0

CHANG DAVID D EVP, R&D, CHIEF MEDICAL OFF.

  • Officer
No longer subject to file 2017-10-03 0

TOMASELLO SHAWN CHIEF COMMERCIAL OFFICER

  • Officer
No longer subject to file 2017-10-03 0

MOORE TIMOTHY L. EVP, TECHNICAL OPERATIONS

  • Officer
No longer subject to file 2017-10-03 0

JENKINSON PAUL L CHIEF FINANCIAL OFFICER

  • Officer
No longer subject to file 2017-10-03 0

WITTE OWEN N.

  • Director
No longer subject to file 2017-10-03 0

KAZAM JOSHUA A

  • Director
No longer subject to file 2017-09-28 0

BELLDEGRUN ARIE CHAIRMAN, PRESIDENT AND CEO

  • Officer
  • Director
3,306,429 2017-09-25 0

ROBERTS MARGO R CHIEF SCIENTIFIC OFFICER

  • Officer
10,655 2016-03-15 0

SPROULE RIZWANA F VP REGULATORY AFFAIRS

  • Officer
10,211 2016-03-15 0

BETTER MARC VP, PRODUCT SCIENCES

  • Officer
7,688 2016-02-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments